Impact of COVID-19 Pandemic on Patients with Atopic Dermatitis. 2022

M R Pourani, and R Ganji, and T Dashti, and S Dadkhahfar, and M Gheisari, and F Abdollahimajd, and M Shahidi Dadras
Skin Research Center, Shahid Beheshti University of Medical Sciences, Teherán, Iran.

Atopic dermatitis (AD) is a chronic skin disease that may be triggered by psychological conditions and several allergens. Patients with AD may be experienced disease exacerbation due to the COVID-19 pandemic lifestyle including home-quarantine and increased stress. We obtained the electronic data of 100 AD patients admitted to our hospital from 2016 to 2019 and called them with specific phone line. Out of 100 patients, 43 were male, and 57 were female (mean age ± SD: 45.85 ± 16.90). Sixty patients (37 females and 23males; mean age: 42.22 ± 14.71) confronted disease flare-up during the COVID-19 era. Exacerbation of AD was correlated with treatment dose alteration, a lengthy history of atopic dermatitis, eczema duration, self-isolation, frequent handwashing, hand disinfection, and POEM scoring (P < 0.05). Regarding the POEM scoring, 61 patients with moderate to severe AD experienced higher anxiety than 39 patients with silent to mild AD (P = 0.013). In this study, most patients experienced disease exacerbation and perceived mild anxiety in this pandemic.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D003876 Dermatitis, Atopic A chronic inflammatory genetically determined disease of the skin marked by increased ability to form reagin (IgE), with increased susceptibility to allergic rhinitis and asthma, and hereditary disposition to a lowered threshold for pruritus. It is manifested by lichenification, excoriation, and crusting, mainly on the flexural surfaces of the elbow and knee. In infants it is known as infantile eczema. Eczema, Atopic,Eczema, Infantile,Neurodermatitis, Atopic,Neurodermatitis, Disseminated,Atopic Dermatitis,Atopic Eczema,Atopic Neurodermatitis,Disseminated Neurodermatitis,Infantile Eczema
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000086382 COVID-19 A viral disorder generally characterized by high FEVER; COUGH; DYSPNEA; CHILLS; PERSISTENT TREMOR; MUSCLE PAIN; HEADACHE; SORE THROAT; a new loss of taste and/or smell (see AGEUSIA and ANOSMIA) and other symptoms of a VIRAL PNEUMONIA. In severe cases, a myriad of coagulopathy associated symptoms often correlating with COVID-19 severity is seen (e.g., BLOOD COAGULATION; THROMBOSIS; ACUTE RESPIRATORY DISTRESS SYNDROME; SEIZURES; HEART ATTACK; STROKE; multiple CEREBRAL INFARCTIONS; KIDNEY FAILURE; catastrophic ANTIPHOSPHOLIPID ANTIBODY SYNDROME and/or DISSEMINATED INTRAVASCULAR COAGULATION). In younger patients, rare inflammatory syndromes are sometimes associated with COVID-19 (e.g., atypical KAWASAKI SYNDROME; TOXIC SHOCK SYNDROME; pediatric multisystem inflammatory disease; and CYTOKINE STORM SYNDROME). A coronavirus, SARS-CoV-2, in the genus BETACORONAVIRUS is the causative agent. 2019 Novel Coronavirus Disease,2019 Novel Coronavirus Infection,2019-nCoV Disease,2019-nCoV Infection,COVID-19 Pandemic,COVID-19 Pandemics,COVID-19 Virus Disease,COVID-19 Virus Infection,Coronavirus Disease 2019,Coronavirus Disease-19,SARS Coronavirus 2 Infection,SARS-CoV-2 Infection,Severe Acute Respiratory Syndrome Coronavirus 2 Infection,COVID19,2019 nCoV Disease,2019 nCoV Infection,2019-nCoV Diseases,2019-nCoV Infections,COVID 19,COVID 19 Pandemic,COVID 19 Virus Disease,COVID 19 Virus Infection,COVID-19 Virus Diseases,COVID-19 Virus Infections,Coronavirus Disease 19,Disease 2019, Coronavirus,Disease, 2019-nCoV,Disease, COVID-19 Virus,Infection, 2019-nCoV,Infection, COVID-19 Virus,Infection, SARS-CoV-2,Pandemic, COVID-19,SARS CoV 2 Infection,SARS-CoV-2 Infections,Virus Disease, COVID-19,Virus Infection, COVID-19
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D012720 Severity of Illness Index Levels within a diagnostic group which are established by various measurement criteria applied to the seriousness of a patient's disorder. Illness Index Severities,Illness Index Severity
D058873 Pandemics Epidemics of infectious disease that have spread to many countries, often more than one continent, and usually affecting a large number of people. Pandemic
D018450 Disease Progression The worsening and general progression of a disease over time. This concept is most often used for chronic and incurable diseases where the stage of the disease is an important determinant of therapy and prognosis. Clinical Course,Clinical Progression,Disease Exacerbation,Exacerbation, Disease,Progression, Clinical,Progression, Disease

Related Publications

M R Pourani, and R Ganji, and T Dashti, and S Dadkhahfar, and M Gheisari, and F Abdollahimajd, and M Shahidi Dadras
February 2022, International journal of environmental research and public health,
M R Pourani, and R Ganji, and T Dashti, and S Dadkhahfar, and M Gheisari, and F Abdollahimajd, and M Shahidi Dadras
August 2023, Acta dermatovenerologica Croatica : ADC,
M R Pourani, and R Ganji, and T Dashti, and S Dadkhahfar, and M Gheisari, and F Abdollahimajd, and M Shahidi Dadras
November 2023, Cutis,
M R Pourani, and R Ganji, and T Dashti, and S Dadkhahfar, and M Gheisari, and F Abdollahimajd, and M Shahidi Dadras
January 2021, Clinics in dermatology,
M R Pourani, and R Ganji, and T Dashti, and S Dadkhahfar, and M Gheisari, and F Abdollahimajd, and M Shahidi Dadras
August 2020, Journal of the American Academy of Dermatology,
M R Pourani, and R Ganji, and T Dashti, and S Dadkhahfar, and M Gheisari, and F Abdollahimajd, and M Shahidi Dadras
February 2024, The journal of allergy and clinical immunology. Global,
M R Pourani, and R Ganji, and T Dashti, and S Dadkhahfar, and M Gheisari, and F Abdollahimajd, and M Shahidi Dadras
January 2023, Revista alergia Mexico (Tecamachalco, Puebla, Mexico : 1993),
M R Pourani, and R Ganji, and T Dashti, and S Dadkhahfar, and M Gheisari, and F Abdollahimajd, and M Shahidi Dadras
January 2022, Frontiers in allergy,
M R Pourani, and R Ganji, and T Dashti, and S Dadkhahfar, and M Gheisari, and F Abdollahimajd, and M Shahidi Dadras
March 2022, JAAD international,
M R Pourani, and R Ganji, and T Dashti, and S Dadkhahfar, and M Gheisari, and F Abdollahimajd, and M Shahidi Dadras
September 2022, International journal of environmental research and public health,
Copied contents to your clipboard!